Corvus Pharmaceuticals, Inc. (CRVS): Price and Financial Metrics
CRVS Price/Volume Stats
| Current price | $1.40 | 52-week high | $4.19 |
| Prev. close | $1.41 | 52-week low | $0.98 |
| Day low | $1.36 | Volume | 58,800 |
| Day high | $1.44 | Avg. volume | 207,528 |
| 50-day MA | $1.95 | Dividend yield | N/A |
| 200-day MA | $1.86 | Market Cap | 68.65M |
CRVS Stock Price Chart Interactive Chart >
Corvus Pharmaceuticals, Inc. (CRVS) Company Bio
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. The company was founded in 2014 and is based in Burlingame, California.
Latest CRVS News From Around the Web
Below are the latest news stories about CORVUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRVS as an investment opportunity.
What Makes Corvus (CRVS) a New Buy StockCorvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma TrialFigure 1: Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for Peripheral T Cell Lymphoma. The plot shows the best percent change in tumor volume in the 21 evaluable patients (eligible patient population) that were measurable by CT scan or by mSWAT for patients with cutaneous involvement. Figure 2: Swimmer Plot of Eligible Patient Population (N=21 evaluable, blue) and Ineligible Patient Population (N=11 evaluable, gray). Tumor histologies are al |
Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year. |
Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year. |
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call TranscriptCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript November 7, 2023 Corvus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.16. Operator: Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2023 Business Update and Financial Results Conference Call. At this time, […] |
CRVS Price Returns
| 1-mo | -23.91% |
| 3-mo | -29.65% |
| 6-mo | 20.69% |
| 1-year | 32.08% |
| 3-year | -49.09% |
| 5-year | -66.67% |
| YTD | -20.45% |
| 2023 | 107.06% |
| 2022 | -64.73% |
| 2021 | -32.30% |
| 2020 | -34.56% |
| 2019 | 48.23% |
Loading social stream, please wait...